PT - JOURNAL ARTICLE AU - Richterman, Aaron AU - Dorvil, Nancy AU - Rivera, Vanessa AU - Bang, Heejung AU - Severe, Patrice AU - Lavoile, Kerylyne AU - Pierre, Samuel AU - Apollon, Alexandra AU - Dumond, Emelyne AU - Forestal, Guyrlaine Pierre Louis AU - Rouzier, Vanessa AU - Joseph, Patrice AU - Cremieux, Pierre-Yves AU - Pape, Jean W AU - Koenig, Serena P TI - Predictors of Clinical Outcomes among People with HIV and Tuberculosis Symptoms after Rapid Treatment Initiation in Haiti AID - 10.1101/2024.06.19.24309189 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.19.24309189 4099 - http://medrxiv.org/content/early/2024/06/20/2024.06.19.24309189.short 4100 - http://medrxiv.org/content/early/2024/06/20/2024.06.19.24309189.full AB - Introduction Few studies have evaluated baseline predictors of clinical outcomes among people with HIV starting antiretroviral therapy (ART) in the modern era of rapid ART initiation.Methods We conducted a secondary analysis of a randomized controlled trial of two rapid treatment initiation strategies for people with treatment-naïve HIV and tuberculosis symptoms at an urban clinic in Haiti. We used logistic regression models to assess associations between baseline characteristics and (1) retention in care at 48 weeks, (2) HIV viral load suppression at 48 weeks (among participants who underwent viral load testing), and (3) all-cause mortality.Results 500 participants were enrolled in the study 11/2017-1/2020. Eighty-eight (18%) participants were diagnosed with tuberculosis, and ART was started in 494 (99%). After adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI 0.10-0.46), dolutegravir initiation (AOR 2.57, 95% CI 1.22-5.43), age (AOR 1.42 per 10-year increase, 95% CI 1.01-1.99), and tuberculosis diagnosis (AOR 3.92, 95% CI 1.36-11.28) were significantly associated with retention. Age (AOR 1.36, 95% CI 1.05-1.75), dolutegravir initiation (AOR 1.75, 95% CI 1.07-2.85), and tuberculosis diagnosis (AOR 0.50, 95% CI 0.28-0.89) were associated with viral suppression. Higher CD4 cell count at enrollment (unadjusted odds ratio [OR] 0.69, 95% CI 0.55-0.87) and anemia (OR 4.86, 95% CI 1.71-13.81) were associated with mortality.Conclusions We identified sociodemographic, treatment-related, clinical, and laboratory-based predictors of clinical outcomes. These characteristics may serve as markers of sub- populations that could benefit from additional interventions to support treatment success after rapid treatment initiation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03154320Funding StatementThis study was funded by a grant from the National Institute of Allergy and Infectious Diseases (R01AI131998; primary investigator: SK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of theAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the institutional review boards at the Haitian Group for the Study of Kaposis Sarcoma and Opportunistic Infections (GHESKIO) and Mass General Brigham and Florida International University, and Weill Cornell Medical College.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA deidentified dataset is available online at https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004246 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004246